Ideaya Biosciences

This is the first study in people testing IDE397, a new oral drug, for advanced solid tumors that have a specific genetic change called MTAP deletion and have stopped responding to standard treatments. The main goals are to find safe doses of IDE397 when given alone and when comb…

This early-stage study is testing a new drug called IDE161, both alone and combined with an existing immunotherapy (pembrolizumab), for people with advanced solid tumors that have spread. The main goals are to find safe doses and see if the treatment shows early signs of shrinkin…

This study is testing whether giving a new drug called darovasertib before standard eye cancer treatments helps preserve patients' vision and prevents the need to remove the eye. It involves 520 people with a specific eye cancer called uveal melanoma that hasn't spread. The goal …

This study is testing a new drug called IDE849 for people with certain aggressive cancers, including small cell lung cancer, that have a specific marker called DLL3. The research aims to find safe doses and see if the drug can shrink tumors, either alone or combined with other me…

This early-stage study is testing a new drug, IDE892, both alone and in combination with another drug called IDE397. It is for adults with advanced solid tumors that have a specific genetic change called MTAP deletion and have stopped responding to standard treatments. The main g…

This study is testing a new drug called IDE196, both alone and combined with other drugs, for people with advanced cancers that have specific genetic changes (GNAQ/11 mutations or PRKC fusions). The main goals are to find safe doses and see if the treatments can shrink tumors. It…